MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, announce an Investigational New Drug (IND) filing by argenx, supported by data from MIMETAS.

The preclinical collaboration focused on investigating the effects of a novel candidate in a human in vitro disease assay in MIMETAS’ OrganoPlate platform. Its results contributed to an IND application by argenx, representing an important milestone for both companies. The research seamlessly aligns with the goals set forth by the 2022 FDA Modernization Act 2.0, emphasizing the use of in vitro models to investigate the safety and effectiveness of drugs.

“By embracing advanced human in vitro models over traditional methods like 2D cell culture and animal models, we can bridge a critical gap towards advancing new therapies,” states MIMETAS CEO Jos Joore. “This project exemplifies our unwavering dedication to advancing new therapies and improving patient outcomes in collaboration with such outstanding partners as argenx.”

About MIMETAS

MIMETAS (Leiden, The Netherlands) is a global leader in human-relevant disease models for drug discovery and development. Based on its proprietary OrganoPlate? platform, MIMETAS has developed a broad spectrum of disease assays with unrivalled physiological comprehensiveness. The company deploys its disease models in partnerships with the global top-50 pharmaceutical industry to find and develop first-in-class targets and compounds. MIMETAS was founded in 2013 in Leiden, the Netherlands, and has grown into a multinational company with operations in Europe, Asia, and the USA. To learn more about MIMETAS's disease modeling capabilities and its OrganoPlate? platform, please visit www.mimetas.com.